Pharmaceuticals Singapore

Singapore AAV Gene Therapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Singapore AAV Gene Therapy Market Industry Trends and Forecast to 2034: Segmented by (Indication, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Singapore · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.0 Mn Placeholder estimate
Estimate 2025 $6.0 Mn 0.1% of the global market
Projected 2034 $33.1 Mn 451.9% Adds $27.1 Mn over 9 forecast years
CAGR 2025–2034 20.9% Faster than 88% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Singapore is 0.12% of the global market.
  • In APAC, the largest is China at $382.4 Mn.
  • Fastest growing: India at 23.4% a year.
  • Singapore ranks 9th of 10 by size in APAC.

Market size projection

Singapore

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$27.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
AAV Gene Therapy Market market size by year, Singapore
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.0 Mn — —
2025 (base) $6.0 Mn +$1.0 Mn —
2026 (forecast) $7.2 Mn +$1.3 Mn +20.9%
2027 (forecast) $8.8 Mn +$1.5 Mn +46.2%
2028 (forecast) $10.6 Mn +$1.8 Mn +76.7%
2029 (forecast) $12.8 Mn +$2.2 Mn +113.7%
2030 (forecast) $15.5 Mn +$2.7 Mn +158.3%
2031 (forecast) $18.7 Mn +$3.2 Mn +212.3%
2032 (forecast) $22.6 Mn +$3.9 Mn +277.6%
2033 (forecast) $27.4 Mn +$4.7 Mn +356.5%
2034 (forecast) $33.1 Mn +$5.7 Mn +451.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.90 Bn
  2. North America $2.65 Bn
  3. US $2.26 Bn
  4. APAC $987.4 Mn
  5. Europe $815.5 Mn
  6. China $382.4 Mn
  7. Canada $365.2 Mn
  8. Japan $292.7 Mn
  9. Latin America $224.7 Mn
  10. Middle East $204.8 Mn
  11. Germany $152.9 Mn
  12. France $146.7 Mn
  13. Brazil $142.2 Mn
  14. UK $111.2 Mn
  15. Italy $112.9 Mn
  16. Ecuador $107.1 Mn
  17. India $105.8 Mn
  18. Spain $92.5 Mn
  19. Saudi Arabia $87.4 Mn
  20. Mexico $79.6 Mn
  21. Africa $74.5 Mn
  22. Russia $58.5 Mn
  23. Australia $53.8 Mn
  24. New Zealand $48.0 Mn
  25. South Africa $36.5 Mn
  26. UAE $24.6 Mn
  27. Egypt $14.4 Mn
  28. Philippines $11.1 Mn
  29. Hong Kong $8.9 Mn
  30. Malaysia $8.7 Mn
  31. Singapore (this report) $6.0 Mn
  32. Thailand $5.7 Mn
  33. Kenya $3.1 Mn

Report snapshot

Singapore AAV Gene Therapy Market Analysis at a glance
Market size, 2025$6.0 Mn placeholder estimate
Forecast, 2034$33.1 Mn placeholder estimate
Growth (CAGR), 2025–203420.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsIndication, route and end user (see all)
Key playersNovartis AG, Sarepta Therapeutics, BioMarin, CSL Behring, Ultragenyx and 1 more (see all)
Regulator in SingaporeHSASource: Health Sciences Authority. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Singapore AAV Gene Therapy Market Analysis Executive Summary

AAV gene therapies use harmless adeno-associated viruses to deliver working genes into cells, often as a one-time treatment.

Key segments of the AAV Gene Therapy market include indication (Neuromuscular Diseases, Hemophilia and Eye Diseases) and route (Intravenous, Subretinal and Intrathecal).

Bar chart: Singapore AAV Gene Therapy market size, 2024–2034, placeholder estimates. $5.0 Mn in 2024, $6.0 Mn in 2025 and $33.1 Mn in 2034, 20.9% CAGR.
Singapore AAV Gene Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Singapore AAV Gene Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the AAV Gene Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the AAV Gene Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the AAV Gene Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for AAV Gene Therapy Market in Singapore

The AAV Gene Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for AAV Gene Therapy Market in Singapore

AAV Gene Therapy in Singapore: rules and payment

Therapeutic products need registration with the Health Sciences Authority (HSA).⁠[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.⁠[2]

[1] Health Sciences Authority. Checked 14 Nov 2026.

[2] CPF Board, MediShield Life. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AAV Gene Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in AAV Gene Therapy right now, from free public sources.

Latest research 448 papers since 2021 (worldwide)

  1. Focused ultrasound-mediated AAV gene therapy: Unlocking a new space in the CNS delivery landscape. Molecular therapy : the journal of the American Society of Gene Therapy, 2026
  2. Preclinical sustained analgesia and translational potential of AAV-encoded Ca(V)3.2 peptide aptamers for peripherally targeted pain therapy. Molecular therapy. Nucleic acids, 2026
  3. Future directions and challenges of drug development and non-human primate models. Life sciences, 2026
  4. Restoring Parkin function: an AAV gene therapy approach for early-onset Parkinson's disease. Frontiers in molecular neuroscience, 2026
  5. Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products. Haematologica, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

AAV Gene Therapy in context

Singapore compared

  • Health spending per person: 3,922 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.83 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.2% of people (2025). World: 10.4% of people (2025). 7th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the AAV Gene Therapy market in Singapore?
Placeholder estimate: about $6.0 Mn in 2025, rising to about $33.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the AAV Gene Therapy market in Singapore growing?
Placeholder estimate: about 20.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the AAV Gene Therapy market report cover?
The report splits the market by indication (Neuromuscular Diseases, Hemophilia, Eye Diseases, Metabolic Disorders), route (Intravenous, Subretinal, Intrathecal) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the AAV Gene Therapy market?
Key players include Novartis AG, Sarepta Therapeutics, BioMarin, CSL Behring, Ultragenyx and REGENXBIO.
What is driving the AAV Gene Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the AAV Gene Therapy market.
Who regulates AAV Gene Therapy in Singapore?
Therapeutic products need registration with the Health Sciences Authority (HSA). Source: Health Sciences Authority. Checked 14 Nov 2026.
How is healthcare paid for in Singapore?
MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts. Source: CPF Board, MediShield Life. Checked 14 Nov 2026.
How much research is published on AAV Gene Therapy?
PubMed lists 448 papers on AAV Gene Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about AAV Gene Therapy in Singapore? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Singapore

See all
Same topic, other categories

Related on cell and gene therapy and genomics

See the topic